loading
Werewolf Therapeutics Inc stock is traded at $1.39, with a volume of 64,260. It is down -0.71% in the last 24 hours and up +11.20% over the past month. Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$1.40
Open:
$1.42
24h Volume:
64,260
Relative Volume:
0.13
Market Cap:
$62.37M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-1.3365
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
+2.96%
1M Performance:
+11.20%
6M Performance:
-3.47%
1Y Performance:
-52.72%
1-Day Range:
Value
$1.39
$1.43
1-Week Range:
Value
$1.33
$1.50
52-Week Range:
Value
$0.595
$4.18

Werewolf Therapeutics Inc Stock (HOWL) Company Profile

Name
Name
Werewolf Therapeutics Inc
Name
Phone
617-952-0555
Name
Address
200 TALCOTT AVENUE, WATERTOWN
Name
Employee
46
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
HOWL's Discussions on Twitter

Compare HOWL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HOWL
Werewolf Therapeutics Inc
1.39 62.82M 19.94M -37.37M -33.38M -1.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-03-24 Initiated JMP Securities Mkt Outperform
Aug-24-23 Initiated Wedbush Outperform
Jun-06-23 Resumed Jefferies Buy
Sep-10-21 Initiated BofA Securities Buy
May-25-21 Initiated Evercore ISI Outperform
May-25-21 Initiated H.C. Wainwright Buy
May-25-21 Initiated Jefferies Buy
May-25-21 Initiated SVB Leerink Outperform
View All

Werewolf Therapeutics Inc Stock (HOWL) Latest News

pulisher
Jul 23, 2025

What drives Werewolf Therapeutics Inc. stock priceSky-high return potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Werewolf Therapeutics Inc. a good long term investmentRapidly growing investment returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Werewolf Therapeutics Inc. Stock Analysis and ForecastSuperior stock selection - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Werewolf Therapeutics Inc. stockHigh-velocity gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Werewolf Therapeutics Inc. stock performs during market volatilityFree Stock Trading Community - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Why Werewolf Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Shares - Newser

Jul 22, 2025
pulisher
Jul 15, 2025

What makes Werewolf Therapeutics Inc. stock price move sharplyInvestor Favorite Picks - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Vontobel Holding Ltd. Acquires New Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jul 10, 2025
pulisher
Jul 09, 2025

Werewolf Therapeutics to Present Innovative IL-2 INDUKINE Development at KidneyCAN 7th Annual Kidney Cancer Research Summit - Nasdaq

Jul 09, 2025
pulisher
Jul 09, 2025

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit - GlobeNewswire

Jul 09, 2025
pulisher
Jul 07, 2025

Werewolf Therapeutics: A High-Risk, High-Potential Bet in Cancer Immunotherapy - criticalcontrolroomworld.com

Jul 07, 2025
pulisher
Jul 05, 2025

Werewolf Therapeutics (NASDAQ:HOWL) Trading Up 1% – What’s Next? - Defense World

Jul 05, 2025
pulisher
Jun 13, 2025

Werewolf Therapeutics Adopts New Bylaws and Elects Directors - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Sells 87,168 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewswire

Jun 12, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Acquires 39,564 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Sells 117,200 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Millennium Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 03, 2025

Deutsche Bank AG Buys 83,172 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 03, 2025
pulisher
Jun 01, 2025

Northern Trust Corp Acquires 16,640 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 01, 2025
pulisher
Jun 01, 2025

Bank of America Corp DE Lowers Stock Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Werewolf Therapeutics Announces Q1 2025 Financial Results - MSN

May 31, 2025
pulisher
May 29, 2025

Werewolf Therapeutics Leaders to Reveal Latest Cancer Treatment Progress at Major Healthcare Conference - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Werewolf Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewswire

May 29, 2025

Werewolf Therapeutics Inc Stock (HOWL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Cap:     |  Volume (24h):